Etomoxir has been described as a selective inhibitor of CPT1 and thus has been widely used to examine the functional roles of fatty acid oxidation in multiple disease states including cardiac ischemia, heart failure, diabetes, and obesity. This evidence concerns the gene CPT2 and obesity due to melanocortin 4 receptor deficiency.